Related references
Note: Only part of the references are listed.Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity
Kevin H. Lin et al.
CELL METABOLISM (2019)
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials
Jorge E. Cortes et al.
FUTURE ONCOLOGY (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
Warren Fiskus et al.
BLOOD CANCER JOURNAL (2019)
BET Proteins as Targets for Anticancer Treatment
Anastasios Stathis et al.
CANCER DISCOVERY (2018)
The Evolution and Ecology of Resistance in Cancer Therapy
Robert Gatenby et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
A Convergence-Based Framework for Cancer Drug Resistance
David J. Konieczkowski et al.
CANCER CELL (2018)
Drug-Driven Phenotypic Convergence Supports Rational Treatment Strategies of Chronic Infections
Lejla Imamovic et al.
CELL (2018)
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Liqin Wang et al.
CELL (2018)
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
A. Esteve-Arenys et al.
ONCOGENE (2018)
Lethal trap created by adaptive evolutionary response to an exotic resource
Michael C. Singer et al.
NATURE (2018)
Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
Ryan S. Soderquist et al.
NATURE COMMUNICATIONS (2018)
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
Haley E. Ramsey et al.
CANCER DISCOVERY (2018)
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
Stefanie Goellner et al.
NATURE MEDICINE (2017)
Mechanisms Regulating PRC2 Recruitment and Enzymatic Activity
Daniel Holoch et al.
TRENDS IN BIOCHEMICAL SCIENCES (2017)
Tumor Evolution as a Therapeutic Target
Nabil Amirouchene-Angelozzi et al.
CANCER DISCOVERY (2017)
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence
Katherine R. Singleton et al.
CELL REPORTS (2017)
Targeting Cancer Cells with BET Bromodomain Inhibitors
Yali Xu et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer
Richard L. Bennett et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
Boyang Zhao et al.
CELL (2016)
Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells
Kimberley A. Beaumont et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shaokun Shu et al.
NATURE (2016)
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer
Daniel Dauch et al.
NATURE MEDICINE (2016)
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Celine Berthon et al.
LANCET HAEMATOLOGY (2016)
Targeting the Adaptability of Heterogeneous Aneuploids
Guangbo Chen et al.
CELL (2015)
c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia
Bing Xia et al.
LEUKEMIA RESEARCH (2015)
The evolutionary history of lethal metastatic prostate cancer
Gunes Gundem et al.
NATURE (2015)
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Philipp Rathert et al.
NATURE (2015)
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong et al.
NATURE (2015)
Can oncology recapitulate paleontology? Lessons from species extinctions
Viola Walther et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Joel D. Leverson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric et al.
NATURE (2015)
EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation
William D. Bradley et al.
CHEMISTRY & BIOLOGY (2014)
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
W. Fiskus et al.
LEUKEMIA (2014)
Measuring error rates in genomic perturbation screens: gold standards for human functional genomics
Traver Hart et al.
MOLECULAR SYSTEMS BIOLOGY (2014)
Inhibition of c-Myc Overcomes Cytotoxic Drug Resistance in Acute Myeloid Leukemia Cells by Promoting Differentiation
Xiao-Na Pan et al.
PLOS ONE (2014)
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
Sarah K. Knutson et al.
PLOS ONE (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
Genetic Screens in Human Cells Using the CRISPR-Cas9 System
Tim Wang et al.
SCIENCE (2014)
Advances and limits of using population genetics to understand local adaptation
Peter Tiffin et al.
TRENDS IN ECOLOGY & EVOLUTION (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
BIM Is the Primary Mediator of MYC-Induced Apoptosis in Multiple Solid Tissues
Nathiya Muthalagu et al.
CELL REPORTS (2014)
MYC Degradation
Amy S. Farrell et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
MYC Acts via the PTEN Tumor Suppressor to Elicit Autoregulation and Genome-Wide Gene Repression by Activation of the Ezh2 Methyltransferase
Mandeep Kaur et al.
CANCER RESEARCH (2013)
CREB-binding protein (CBP) regulates β-adrenoceptor (β-AR) - mediated apoptosis
Y. Y. Lee et al.
CELL DEATH AND DIFFERENTIATION (2013)
BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response
Kristopher A. Sarosiek et al.
MOLECULAR CELL (2013)
Ecological genomics of local adaptation
Outi Savolainen et al.
NATURE REVIEWS GENETICS (2013)
BH3 profiling in whole cells by fluorimeter or FACS
Jeremy Ryan et al.
METHODS (2013)
Ecological novelty and the emergence of evolutionary traps
Bruce A. Robertson et al.
TRENDS IN ECOLOGY & EVOLUTION (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
Thanh-Trang Vo et al.
CELL (2012)
Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3
Yupeng Zheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1
Mario Campone et al.
MOLECULAR CANCER (2011)
Histone Methylation by PRC2 Is Inhibited by Active Chromatin Marks
Frank W. Schmitges et al.
MOLECULAR CELL (2011)
The Polycomb complex PRC2 and its mark in life
Raphael Margueron et al.
NATURE (2011)
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Triona Ni Chonghaile et al.
SCIENCE (2011)
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state
Juergen den Hollander et al.
BLOOD (2010)
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
Warren Fiskus et al.
BLOOD (2009)
Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells
Jie Cai et al.
CANCER RESEARCH (2008)
p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa
A Villunger et al.
SCIENCE (2003)
Ecological and evolutionary traps
MA Schlaepfer et al.
TRENDS IN ECOLOGY & EVOLUTION (2002)
PUMA, a novel proapoptotic gene, is induced by p53
K Nakano et al.
MOLECULAR CELL (2001)
Share Paper
